Abstract:Abstract 2384 Introduction: Allogeneic haematopoietic stem cell transplantation (HSCT) has been used to treat malignant hematological diseases. For patients who do not have a matched sibling donor or a matched unrelated donor (MUD) for transplantation, an eligible HLA-haploidentical donor can be identified rapidly in nearly all cases. However, HLA-haploidentical BMT has been associated with significant risks of complication, such as graft rejection and severe GVHD and infection. Materials and Methods: Thirty eight consecutive patients with malignant hematological diseases received HLA-haploidentical stem cell transplant from April 2008 to June 2010. Eligible patients were 9– 48 years of age with acute myeloid leukemia (n=10),acute lymphocytic leukemia (n=17), myelodysplastic syndrome(n=5), chronic myeloid leukemia (n=4), non Hodgkin lymphoma (n=2). Transplantation conditioning consisted of Ara-C (4 g/m2/d, i.v.) on day -10 and -9, Bu (9.6mg/kg i.v. in 12 doses) on day -8, -7 and -6, Cy (1.8 g/m2/d, i.v.) on day -5 and -4, Me-CCNU (250 mg/kg, i.v.) on day -3, and ATG (2.5 mg/kg/d i.v.) on day -5 to -2. The prophylaxis of aGVHD consisted of cyclosporine A (CsA), mycophenolate mofetil (MMF), and short-term methotrexate. Donors were primed with rhG-CSF (7.5 mg/kg per day) injected subcutaneous (s.c.). Bone marrow cells and peripheral blood stem cells(PBSC) were harvested in nineteen donors, and only PBSC were harvested in the other 19 donors. Results: Primary engraftment was achieved in all patients. All the patients achieved complete donor chimerism in the peripheral blood before day +28. Seven patients (18.4%) had grade I aGVHD, ten (26.3%) had grade II aGVHD, four(10.5%) had grade III aGVHD and four (10.5%) had grade IV aGVHD. II-IV aGVHD occurred in nine patients treated with bone marrow cells and PBSCs, the same number patients suffered from II-IV aGVHD treated with only PBSCs. Transplant related mortality within 100 days after transplantation was 15.8%. At a median follow-up of 10 months (range 2–28months), the overall survival was 68.4%. Conclusion: Haploidentical stem cell transplantation is relatively safe and efficient for the patients who have no HLA matched donors.The results require to confirm and show that G-BM combined with PBSC or G-PBSC from haploidentical family donors have equal effect. Disclosures: No relevant conflicts of interest to declare.

Treatment for beta-thalassemia with hematopoietic stem cell transplantation

Hematopoietic stem cell transplantation for children with thalassemia major in China.

Hematopoietic Stem Cell Transplantation for Children with Thalassemia Major in China

Allogeneic Hematopoietic Stem Cell Transplantation for Β-Thalassemia Major Patients Using a Reduced-Intensity Conditioning Regimen

Hla-Haploidentical Stem Cell Transplantation for Malignant Hematological Diseases Using G-Csf Mobilized Bone Marrow and Peripheral Blood Stem Cells

[Allogeneic Peripheral Blood Stem Cell Transplantation for 3 Patients with Beta-Thalassemia Major and 1 Patient with Congenital Idiopathic Haemolytic Anemia].

Unrelated donor allogeneic peripheral blood stem cell transplantation for beta-thalassemia major in one case

[The Clinical Efficacy of Haploidentical Hematopoietic Stem Cell Transplantation by Using Parental Donors in Patients with Thalassemia].

Hematopoietic Stem Cell Transplantation for Children with Β-Thalassemia Major: Multicenter Experience in China.

Clinical study of unrelated mismatched hematopoietic stem cell transplantation for β-thalassemia major

Hematopoietic stem cell transplantation of non-cryopreserved sibling umbilical cord blood for major thalassaemia in children: a report of 9 cases

Modified Conditioning Regimen Improves Outcomes of Unrelated Donor Peripheral Blood Stem Cell Transplantation for Β‐thalassaemia Major Patients

Current status of beta‐thalassemia and its treatment strategies

β-Thalassemia gene editing therapy: Advancements and difficulties

PD02 A Literature Review Of Treatment Schemes And Effects For Beta Thalassemia In China

Comparison of Hematopoietic Stem Cell Transplantation Results in Patients with β-Thalassemia Major from Three Different Graft Types

Umbilical cord blood transplantation in Chinese children with beta-thalassemia.

ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN Β -THALASSEMIA

Allogeneic peripheral blood stem cell transplantation for hereditary haemolytic anemia

Transplantation with Combination of Umbilical Cord Blood and Neonatal Peripheral Blood in the Treatment of A Patient with Β-Thalassemia Major

Efficacy and Security of a New Cladribine-Based Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Children with Major Thalassemia